The peptide therapeutics market size is projected to reach US$ 73.63 billion by 2031 from US$ 29.35 billion in 2023. The market is expected to register a CAGR of 11.5% in 2023–2031. Growing popularity reducing the pace of manufacturing of peptide drugs and adoption of new technologies are likely to remain key peptide therapeutics market trends.

Peptide Therapeutics Market Analysis

As the global burden of chronic diseases increases, the demand for targeted and efficient therapeutic approaches increases. With their precision and specificity, peptide therapeutics are proving to be a compelling solution that meets the therapeutic needs of various chronic diseases. Robust research pipelines promise a future full of novel and breakthrough peptide therapeutics. The shift toward personalized medicine is consistent with the unique properties of peptide therapeutics. As peptides show promise in treating rare diseases, pharmaceutical companies focus on developing therapeutic solutions for niche patient populations. Innovations in synthetic methods lead to more complex and specialized peptides, expanding the therapeutic arsenal available to healthcare professionals. Further, combined efforts in research initiatives between scientists and market players drive innovation in the peptide therapeutics market. Additionally, partnerships and alliances create synergies that advance the development of cutting-edge peptide-based therapies. However, stringent regulations and high drug development costs are expected to restrain market growth.

Peptide Therapeutics Market Overview

The peptide therapeutics market is emerging as a dynamic and promising sector within the pharmaceutical industry, offering a unique approach to treating various diseases and medical conditions. Peptide therapeutics composed of short amino acid sequences have attracted considerable attention due to their specificity, efficacy, and potential applications in various therapeutic areas. This emerging market stands at the intersection of innovation and medical science and is poised to reshape the healthcare landscape. The market includes various peptides, from naturally occurring to synthetic analogs, designed for improved therapeutic results. These peptides are versatile agents targeting specific receptors, enzymes, or cellular mechanisms, making them a valuable tool in precision medicine.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Peptide Therapeutics Market: Strategic Insights

Peptide Therapeutics Market

• 
  CAGR (2023 - 2031)

  11.5%
• Market Size 2023
  US$ 29.35 Billion
• Market Size 2031
  US$ 73.63 Billion

Market Dynamics

GROWTH DRIVERS

• Growing Investments on Peptide Therapeutics

FUTURE TRENDS

• Emphasis on Automatic Peptide Synthesis

OPPORTUNITIES

• Operational Limitations of Peptides

Key Players

• Eli Lilly and Company,
• Amgen Inc.,
• Teva Pharmaceutical Industries Ltd.,
• Lonza,
• Sanofi,
• Bristol-Myers Squibb Company,
• GlaxoSmithKline plc.,
• AstraZeneca,
• Pfizer Inc.,
• Novo Nordisk

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type

• Generic
• Innovative

Route of Administration

• Parenteral
• Oral
• Mucosal
• Pulmonary
• Others

Synthesis Technology

• Solid Phase Peptide Synthesis

Application

• Cancer
• Cardiovascular Disorder
• Metabolic Disorder
• Respiratory Disorder
• Pain MAnagement
• Dermatology

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Peptide Therapeutics Market Drivers and Opportunities

Increasing Prevalence of Metabolic Disorders and Infectious Diseases to Favor Market

As per an article in the National Library of Medicine, infectious diseases remain a leading cause of sickness and mortality worldwide, causing more than 52 million deaths per year worldwide. According to the IDF published in December 2021, an estimated 14 million adults in Mexico have diabetes. Peptides such as amide (GLP-1) are effective in treating diabetes. In February 2022, the Nova Scotia provincial government reported that Nova Scotians have registered in pharmacare programs that would begin switching to a biosimilar version of certain biologic medicines, including some insulins and medications, for the treatment of Crohn's disease and rheumatism. The increasing cases of some metabolic disorders, such as organ dysfunction, genetic disorders, and mitochondrial dysfunction, are one of the factors that drive the market growth. The progressive storage of glucocerebrosides in macrophages, primarily in the bone, bone marrow, spleen, and liver are the indications of Gaucher disease (GD) which is an autosomal recessive lysosomal storage disorder. As per the Journal of Pediatric Haematology/Oncology (JPHO), in July 2022, the prevalence of GD cases per 100,000 live births worldwide was 1.5. Therefore, the high prevalence of infectious and metabolic diseases drives the demand for peptide therapeutics for treating these diseases, thereby boosting market growth.

Strong Pipeline and Applications of Peptide Drugs – An Opportunity for Peptide Therapeutics Market Growth

The most common peptide indications are oncology, endocrinology, and metabolic diseases. Other peptide target areas that have received attention include gastroenterology, cardiovascular disease, dermatology, bone diseases, and sexual dysfunction. Due to their high immunogenicity, peptide vaccines also have great potential to become an alternative to classical vaccines as they are completely synthetic and do not cause undesirable side effects. To overcome their limitations, various modifications of peptides have been introduced. Furthermore, the ongoing studies related to the application of peptides are expected to positively impact the pipeline, thereby providing lucrative opportunities for market growth. Some peptide drug pipelines are as follows:

Company	Peptide	Therapeutic Area	Developmental Stage
3B Pharmaceuticals (Germany)	FAP-2286	Oncology-FAP expressing tumours	Phase-I clinical trials
	3B 401	Neuroendocrine tumors	Pre-clinical trials
Allysta Pharmaceuticals (US)	ALY688	Ophthalmology-Dry eye disease	Phase-II clinical trials
	ALY688SR	Liver diseases and obesity	Phase-I clinical trials

Source: Issar Pharma, Willing Wellness

Peptide Therapeutics Market Report Segmentation Analysis

Key segments that contributed to the derivation of the peptide therapeutics market analysis are component, application, and end user.

• Based on type, the peptide therapeutics market is divided into generic, and innovative. The innovative segment held the largest share of the market in 2023, whereas the generic segment is anticipated to register the highest CAGR during the forecast period.
• By route of administration, the market is segmented into parenteral, oral, mucosal, pulmonary, others. The parenteral segment held the largest share of the market in 2023, and oral segment is anticipated to register the highest CAGR during 2023–2031.
• Based on synthesis technology, the peptide therapeutics market is divided solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), hybrid technology. The solid phase peptide synthesis segment held the largest share of the market in 2023. However, the hybrid technology segment is anticipated to register the highest CAGR during the forecast period.
• In terms of application, the market is segmented into cancer, cardiovascular disorder, metabolic disorder, respiratory disorder, pain, and dermatology. The cancer segment held the largest share of the market in 2023. However, the metabolic disorder segment is estimated to register the highest CAGR during 2023–2031.

Peptide Therapeutics Market Share Analysis by Geography

The geographic scope of the peptide therapeutics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

North America has dominated the peptide therapeutics market. The growth of the market in North America is attributed to the renowned academic institutions, state-of-the-art laboratories, and collaborations between science and industry contribute to a vibrant R&D ecosystem that promotes the discovery and development of novel peptides with therapeutic potential. In North America, the biotechnology sector in plays an important role in developing peptide therapeutics. The presence of leading biotech companies and a supportive regulatory environment promote translating research findings into clinically viable peptide-based treatments, positioning North America as a leader in the global peptide therapeutics space. The prevalence of chronic diseases in North America highlights the need for advanced therapeutic solutions. With their targeted mechanisms of action, peptide therapeutics are proving to be promising candidates for treating diseases such as diabetes, cardiovascular diseases (CVDs), and various types of cancer. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.

Peptide Therapeutics Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Peptide Therapeutics Market News and Recent Developments

The peptide therapeutics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for peptide therapeutics:

• Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved an additional indication for Wegovy to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity. (Novo Nordisk A/S, Press Release, 2024)
• Ono Pharmaceutical Co., Ltd. announced that it entered into a drug discovery collaboration agreement with PeptiDream Inc., to discover and develop novel macrocyclic constrained peptide drugs against multiple targets. Under the terms of the agreement, PeptiDream will identify and optimize macrocyclic constrained peptide drug candidates for multiple targets of interest selected by Ono, by using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. (Source: ONO PHARMACEUTICAL CO., LTD., News, 2023)
• Biosynth, a supplier of critical materials to the life science industry, announced the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply. The acquisition enables the support of all phases of the product life cycle from discovery to commercialisation. (Source: Biosynth, News, 2023)
• IRBM, an innovative contract research organization, announced that it has signed a new agreement with Merck & Co. Inc., to continue their collaboration in the peptide therapeutics area. The collaboration allows to combine IRBM’s first-class scientific expertise in peptide design and synthesis with Merck & Co. Inc.’s exceptional drug development capabilities with a focus on delivering innovative therapies to patients in need. (Source: IRBM S.p.A.; Press Release; 2023)
• Hokkaido University researchers have developed a novel method to design and develop peptide antibiotics in large numbers, which will prove critical to controlling antibiotic resistance. (Hokkaido University, Press Release, 2023)

Peptide Therapeutics Market Report Coverage and Deliverables

The “Peptide Therapeutics Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles